Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daprodustat for anemia in low-risk myelodysplastic syndromes
jRCTs031240080Recruiting
- Sponsor
- Yokohama City University
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of daprodustat in myelodysplastic syndrome (MDS), sponsored by Yokohama City University. Primary endpoint: Hematological improvement-erythroid (HI-E) response rate at 24 weeks. Started May 2024; status: recruiting.
02
Drugs
daprodustat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on jRCTs031240080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240080.